Individualized Starting Dose of Maintenance Niraparib Increases PFS vs Placebo in Ovarian Cancer

The phase 3 PRIME study showed increased progression-free survival for patients with newly diagnosed ovarian cancer who were treated with an individualized starting dose of maintenance niraparib vs placebo.

An individualized starting dose of maintenance niraparib (Zejula) had a statistically significant and clinically meaningful impact on progression-free survival (PFS) compared with placebo regardless of biomarker status for patients with newly diagnosed ovarian cancer, according to results from the phase 3 PRIME study (NCT03709316) that were presented at The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer.

The median PFS in the intent-to-treat (ITT) population was 24.8 months (HR, 0.45; 95% CI, 19.2–not estimated [NE]) in the niraparib arm compared with 8.3 months (95% CI, 7.3-11.1) in the placebo group (HR, 0.45; 95% CI, 0.34-0.60; P <.001). The homologous recombination deficiency (HRD) subgroup had a median PFS that was not reached (NR; 95% CI, 22.3-NE) in the niraparib arm vs 11.0 months (95% CI, 8.3-13.8) in the placebo group (HR, 0.48; 95% CI, 0.34-0.68; P <.001). Additionally, patients with germline

BRCA mutations had a median PFS that was NR (95% CI, 22.3-NE) vs 10.8 months (95% CI, 8.3-19.3) in the niraparib and placebo cohorts, respectively (HR, 0.40; 95% CI, 0.23-0.68 P <.001). Those with non–germline BRCA mutations had a median PFS of 19.3 months (95% CI, 13.8-NE) vs. 8.3 months (95% CI, 5.6-11.2) in the niraparib and placebo groups, respectively (HR, 0.48; 95% CI, 0.34-0.67 P <.001). In the non-gBRCA mutation subgroups, those with non–germline BRCA mutation and who were HRD had a median PFS of 24.8 months (95% CI, 14.0-NE) vs 11.1 months (95% CI, 8.3-13.8) in the niraparib and placebo groups, respectively (HR, 0.58; 95% CI, 0.36-0.93; P = .022). For those with non–germline BRCA mutations who were homologues recombination proficient, the median PFS was 14.0 months (95% CI, 14.0-NE) vs 5.5 months (95% CI, 2.9-7.3) in the niraparib and placebo groups, respectively (HR, 0.41; 95% CI, 0.25-0.65; P <.001).

“PRIME data. Continue to support niraparib monotherapy after first-line platinum-based chemotherapy regardless of biomarker status,” Ning Li, MD, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, said during the presentation.

A total of 384 patients were randomized 2:1 and received either niraparib (n = 255) or placebo (n = 129) for 36 months or until disease progression, death, or unacceptable toxicity. Patients were eligible for treatment if they had FIGO stage III or IV ovarian cancer, a high-grade or serous endometrioid tumor, previous primary or interval cytoprotective surgery despite postoperative residual disease status, and a complete (CR) or partial response (PR) to first-line platinum-based chemotherapy.

Stratification factors included germline BRCA mutational status, tumor HRD status, previous neoadjuvant chemotherapy, and response to first-line platinum chemotherapy. The primary end point was PFS via blinded independent central review in the ITT population. Secondary end points were OS, time to first subsequent anti-cancer therapy in the ITT subgroup, PFS and OS in the HRD subgroup, and safety.

At data cut-off, 102 patients in the niraparib group and 29 in the placebo were still receiving treatment. The median follow-up was 27.5 months.

Patient characteristics included a median age of 53.0 years in the niraparib group vs 54.0 years in the placebo, and a median weight of 59.0 kg in the niraparib group and 57.0 kg in the placebo group. A total of 71.4% of patients in the niraparib group had FIGO stage III disease vs 72.9% in the placebo and 28.6% vs 27.1% of patients in both respective groups had stage IV disease.

A total of 83.1% and 79.8% and a CR to previous platinum-based chemotherapy in the niraparib and chemotherapy groups, respectively. Additionally, prior treatment with chemotherapy resulted in a PR was in 16.9% vs 20.2% of patients in each respective group. A total of 33.3% of patients in the niraparib group and 31.0% in the placebo group had a germline BRCA mutation. Non–germline BRCA mutations were observed in 66.7% of patients in the niraparib group and 69.0% in the placebo group.

At 24 months in the ITT group, 52.6% of patients in the niraparib group and 30.4% in the placebo group did not have progressive disease or death. Those in the HRD subgroup without progressive disease or death included 57.4% in the niraparib group and 33.9% in the placebo group.

OS data were immature in the ITT population (HR, 0.63; 95% CI, 0.38-1.03; P = .061). The median time to first subsequent anti-cancer therapy was 29.2 months (95% CI, 22.4–NE) in the niraparib group and 11.9 months (95% CI, 8.8-14.8) in the placebo group.

“While overall survival [OS] data are still immature, there is a trend in favor of niraparib at this data cut-off,” Li said.

Grade 3 or higher treatment-emergent adverse effects (TRAEs) were observed in 54.5% vs 17.8% of patients in the niraparib and placebo groups, respectively. Grade 3/4 treatment-related AEs were observed in 49.0% vs 7.0% in the niraparib and placebo groups, respectively. Serious TEAEs were observed in 18.8% vs 8.5% of patients in the niraparib and placebo groups, respectively, of which 14.9% vs 3.9% treatment related.

In the niraparib and placebo cohorts, TEAEs relating to treatment interruption were observed in 62.7% vs 19.4%, dose reductions in 40.4% vs 6.2%, discontinuation in 6.7% vs 5.4%, and death in 0.4% vs 0% of patients, respectively. TEAEs of grade 3 or higher observed in more than 20% of patients in the niraparib and placebo cohorts, respectively, were decreased neutrophil count (17.3% vs 1.6%), decreased white blood cell count (6.7% vs 0.8%), anemia (18.0% vs 1.6%), decreased platelet count (14.1% vs 0.8%) and increased glutamyltransferase (5.1% vs 17.1%).

Reference

Li N, Zhu J, Yin R, et al. Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): a randomized, double-blind, placebo-controlled, phase 3 trial. Presented at: 2022 SGO Annual Meeting on Women’s Cancer; March 18-21, 2022. Phoenix, Arizona